source
- Replimune secures FDA accelerated approval for melanoma therapy after two prior rejectionsReplimune, a biotech based in Massachusetts, has received accelerated approval from the U.S. Food and Drug Administration for its melanoma drug. The approval comes after the therapy was rejected tw…
- FDA grants accelerated approval to Replimune’s melanoma therapy Tudriqev after two prior rejectionsThe Food and Drug Administration has granted accelerated approval to Replimune’s RP1 treatment, which will be marketed under the name Tudriqev, for patients with advanced melanoma. An advisory com…